News from Royalty Pharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

04 Mar, 2016, 10:30 ET UCLA sells royalty rights connected with cancer drug to Royalty Pharma for $1.14 billion

 UCLA and Royalty Pharma announced today that UCLA has sold its royalty interest connected with a leading prostate cancer medication, Xtandi,...


12 Feb, 2015, 08:30 ET Royalty Pharma Announces George Lloyd is Named General Counsel

 Royalty Pharma is pleased to announce that George Lloyd has been named General Counsel of Royalty Pharma effective immediately.  Since...


15 Jan, 2015, 11:30 ET Royalty Pharma Announces Greg Norden Joins Investment Committee

 Royalty Pharma is pleased to announce that Greg Norden has joined its Investment Committee. Greg brings more than 25 years of leadership...


19 Nov, 2014, 07:22 ET Royalty Pharma Announces $3.3 Billion Royalty Transaction with Cystic Fibrosis Foundation Therapeutics

Royalty Pharma announced today its acquisition of royalties on Vertex Pharmaceuticals' cystic fibrosis treatments owned by Cystic Fibrosis...


06 May, 2014, 07:00 ET Avillion Announces Royalty Pharma Investment

Avillion LLP, a company focused on co-development and financing of late-stage pharmaceutical candidates from Phase 3 clinical development through...


06 Jan, 2014, 08:00 ET Royalty Pharma Acquires Additional Interest in TECFIDERA® for $510 Million

 Royalty Pharma announced today that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG...


12 Aug, 2013, 07:00 ET Royalty Pharma Partners with Aisling Capital and Clarus Ventures in Recent Ibrutinib Royalty Purchase

 Royalty Pharma announced today that, pursuant to a collaboration with Aisling Capital and Clarus Ventures, it has...


19 Jul, 2013, 08:00 ET Royalty Pharma Announces Marshall Urist, MD, PhD, Joins Management Team

 Royalty Pharma is pleased to announce that Marshall Urist, MD, PhD, has joined the company as Vice President, Research and Investments. ...


18 Jun, 2013, 06:43 ET Royalty Pharma Announces Withdrawal Of Judicial Review And Lapse Of Offer

 Royalty Pharma announced today that it had withdrawn its request for a judicial review of the Irish Takeover Panel's decision requiring it to...


17 Jun, 2013, 10:31 ET Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today

 As the Share Repurchase Resolution has been passed at the Elan EGM earlier today, Royalty Pharma's Offer for Elan Corporation, plc (NYSE: ELN)...


17 Jun, 2013, 02:26 ET Royalty Pharma Chairman Writes Open Letter to Elan Board

 Royalty Pharma announced today that Rory Riggs, Chairman and Co-Founder of the Royalty Pharma group, is sending the following open letter to...


14 Jun, 2013, 13:34 ET Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty

 Royalty Pharma notes today's announcement by Elan Corporation, plc (NYSE: ELN) that it intends to explore a sale of the Company. Royalty...


14 Jun, 2013, 01:41 ET Elan ADS Holders Decisively Vote Against Theravance And AOP Transactions

 Royalty Pharma today announces that as of 3:00 pm EDT on Thursday, June 13, 2013 holders of approximately 311 million Elan ADSs, representing...


13 Jun, 2013, 07:53 ET Royalty Pharma Announces Offer May Lapse (Be Withdrawn)

 Royalty Pharma today announces that as of 5:30 pm EDT on Wednesday, June 12, 2013 holders of approximately 276 million Elan ADSs (NYSE: ELN),...


11 Jun, 2013, 14:25 ET Royalty Pharma Files Judicial Review Proceedings

 Royalty Pharma today announces that it has reluctantly filed judicial review proceedings related to the decision of the Irish Takeover Panel...


11 Jun, 2013, 11:24 ET In Royalty Pharma's View, Elan's EGM Circular is Misleading and Omits Key Information that Elan Shareholders Need to Make an Informed Decision

 Royalty Pharma today announced that it believes Elan's (NYSE: ELN) disclosure in its May 27 EGM Circular is misleading and inadequate,...


11 Jun, 2013, 08:55 ET Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit

 Royalty Pharma announced today that Elan voluntarily withdrew the lawsuit it had filed on an expedited basis only one week ago in New York...


11 Jun, 2013, 02:07 ET Royalty Pharma Acceptances Announcement

 In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act, Echo Pharma Acquisition Limited...


10 Jun, 2013, 18:46 ET Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit

 Royalty Pharma announced today that Elan voluntarily withdrew the lawsuit it had filed on an expedited basis only one week ago in New York...


10 Jun, 2013, 17:18 ET Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan

 Royalty Pharma today posted a new investor presentation summarizing its Further Increased Offer for Elan Corporation, plc (NYSE: ELN) and...


10 Jun, 2013, 06:33 ET Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today

 Royalty Pharma today urged Elan Corporation, plc (NYSE: ELN) Shareholders to immediately vote AGAINST ALL FOUR resolutions Elan's Board has...


10 Jun, 2013, 02:04 ET Royalty Pharma Posts Further Revised Offer Document In Offer For Elan Corporation, Plc ("Elan")

 Following its announcement on 7 June 2013, Echo Pharma Acquisition Limited ("Royalty Pharma") has today issued a further revised offer...


07 Jun, 2013, 06:47 ET Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share

 Royalty Pharma today announced, pursuant to Rule 2.5 of the Irish Takeover Rules (the "Announcement"), a firm intention to further increase...


07 Jun, 2013, 02:08 ET Royalty Pharma Acceptances Announcement

 In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act, Echo Pharma Acquisition Limited...


06 Jun, 2013, 11:18 ET Royalty Pharma Announces Extension of its Increased Offer

Royalty Pharma today announces that the closing date for its Increased Offer made for Elan Corporation, plc (NYSE: ELN) on 23 May 2013 is being...